Results 191 to 200 of about 107,280 (285)

Evolution of Natural Product Scaffolds as Potential Proteasome Inhibitors in Developing Cancer Therapeutics. [PDF]

Metabolites, 2023
Mir RH, Mir PA, Uppal J, Chawla A, Patel M, Bardakci F, Adnan M, Mohi-Ud-Din R.   +7 more
europepmc   +1 more source

CP-09. HTDS ON NOVEL CELL LINES IDENTIFIED BETA-CATENIN INHIBITOR TEGATRABETAN AND PROTEASOME INHIBITOR BORTEZOMIB AS TWO NOVEL POTENTIAL AGENTS AGAINST ADAMANTINOMATOUS CRANIOPHARYNGIOMA [PDF]

Carolina Cocito, Christopher C Padilla, David J. Pisapia, Charli Ann J. Hertz, Nadia Dahmane, Jeffrey P. Greenfield   +5 more
openalex   +1 more source

F‐Box and Leucine‐Rich Repeat Protein 4 (FBXL4) Maintains Sarcomere Integrity and Cardiac Function by Enhancing K48‐Linked Ubiquitinated Degradation of Profilin‐1 (PFN1)

Advanced Science, EarlyView.
Schematic diagram depicting the proposed signaling mechanisms underlying the effects of FBXL4 in the setting of cardiac hypertrophy. Under hypertrophic stimulation, cardiomyocytes‐specific overexpression FBXL4 maintains sarcomere integrity and cardiac function by enhancing K48‐linked ubiquitinated degradation of PFN1 at the K70 site.
Xingda Li, Xueqi He, Xinyuan Hao, Yu Zhang, Xin Zhao, Shuang Wang, Zhenru Wang, Haonan Du, Hongda Li, Lian Yi, Zhimin Du, Weijie Du   +11 more
wiley   +1 more source

Proteasome inhibitors prevent tumor cell proliferation in HHV-8-unrelated PEL-like lymphoma. [PDF]

Leuk Res Rep
Kawauchi K, Ogasawara T.
europepmc   +1 more source

OCTN2 Activates a Non‐Canonical Carnitine Metabolic Pathway to Promote MASH‐HCC Progression and Immunotherapy Resistance

Advanced Science, EarlyView.
In non‐MASH‐HCC, L‐carnitine promotes tumor progression primarily through its classical role in enhancing fatty acid oxidation (FAO). However, in MASH‐HCC, where FAO is markedly suppressed, L‐carnitine shifts from this canonical function to serve instead as an intracellular acetyl group buffer.
Chuqi Xia, Xiao Zhang, Jinze Li, Ning Xu, Sheng Hu, Qiyu Lu, Yuxuan Li, Taifu Xiao, Xu Li, Xue Wang, Kequan Xu, Daoming Liang   +11 more
wiley   +1 more source

High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target. [PDF]

Cancer Res Commun
Yoshimura T, Kamatani T, Ookubo A, Takahashi M, Itoh M, Ebisudani T, Masugi Y, Toyonaga T, Hamamoto J, Saotome K, Sakai K, Yoshihama T, Moritoki N, Shibata S, Yasuda H, Sato T, Sato TA, Aoki D, Yamagami W, Tsunoda T, Chiyoda T.   +20 more
europepmc   +1 more source

Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors [PDF]

, 2018
Phui‐Ly Liew, Rui Huang, Yu‐Chun Weng, Chia‐Lang Fang, Tim H.‐M. Huang, Hung‐Cheng Lai   +5 more
openalex   +1 more source

Non‐Targeting shRNA‐Encoded Plasmid DNA Enhances Protective Immunity Through RIDD‐RIG‐I Signaling Pathway in the Zika Virus Animal Model

Advanced Science, EarlyView.
We present a novel DNA vaccine platform featuring intrinsic, non‐targeting dsRNA that significantly enhances immune responses by activating the regulated IRE1‐dependent decay‐RIG‐I signaling pathway. This research elucidates a previously uncharacterized mechanism for dsRNA‐mediated innate immune activation.
Min‐Syuan Huang, Hung‐Chun Liao, Po Peng, Wan‐Ling Wu, Kit Man Chai, Mei‐Yu Chen, Guann‐Yi Yu, Tsung‐Hsien Chuang, Hsin‐Wei Chen, Chuang‐Rung Chang, Shih‐Jen Liu   +10 more
wiley   +1 more source

Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction. [PDF]

Int J Mol Sci
Tyrna P, Procyk G, Szeleszczuk Ł, Młynarczuk-Biały I.   +3 more
europepmc   +1 more source

Integrin β3 Orchestrates Hepatic Steatosis via a Novel CD36‐Dependent Lipid Uptake Complex

Advanced Science, EarlyView.
In MASH, ITGB3 recruits LYN and drives its ubiquitin‐proteasomal degradation via phosphorylation. This relieves DHHC5 inhibition, enabling ITGB3/DHHC5/CD36 complex assembly to enhance CD36 palmitoylation and fatty acid uptake, thereby exacerbating disease. Targeting ITGB3 blocks this pathogenic axis and ameliorates MASH.
Ying Zhang, Lei Dai, Zhongquan Cui, Ye Zhou, Wenyuan Dong, Hongcheng Jiang, Mengwen Wang, Xiaodan Zhong, Wei Dong, Zhang Yue, Thati Madhusudhan, Hongjie Wang, Xiong Zhong Ruan, Hesong Zeng   +13 more
wiley   +1 more source